<DOC>
	<DOCNO>NCT01498445</DOCNO>
	<brief_summary>The goal clinical research study learn combine Spyrcel ( dasatinib ) Dacogen ( decitabine ) help control CML . The dose level decitabine also study . Dasatinib design block protein responsible chronic myeloid leukemia . Decitabine design affect mechanism cell use control expression certain gene , important progression CML .</brief_summary>
	<brief_title>An Open-Label , Phase I/II Study Two Different Schedules Dasatinib ( Sprycel ) Decitabine ( Dacogen ) Used Combination Patients With Accelerated Blastic Phase Chronic Myelogenous Leukemia ( Protocol CA180357 )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group dose level base join study side effect see . Your doctor discus detail . There 5 dos dasatinib test Phase 1 . The first 3 participant receive low dose therapy . If major side effect see participant , next participant receive high dose . Once dose identify well-tolerated participant , dose use new participant . If Phase 2 , receive dose level test Phase 1 . You receive one 2 dos decitabine . What dose receive determine chance ( like coin toss ) . Study Administration : Each cycle 28 day . You take dasatinib mouth 1 time day . You receive decitabine vein 10 day cycle . If doctor think best interest , may receive decitabine few day cycle ( 5 day instead 10 day ) . Your doctor decide many dos take base side effect may status disease . If severe side effect study drug , study doctor may decide stop drug dose side effect improve . You ask keep study diary review schedule study visit . In diary , record take study drug . Study Visits : At every visit , ask side effect may list drug may take . Every week first 3 cycle every 2-4 week , blood ( 1 tablespoon ) drawn check blood cell count . About 1 week first dose , ECG . Every 1-2 week first 3 cycle every 4-8 week , blood ( 1 tablespoon ) drawn test kidney liver function . Every 1-3 month , blood ( 1 tablespoon ) draw genetic test . Before start Cycle 2 , every 2-4 cycle first year , every 6 cycle , complete physical exam . Before start Cycle 2 , every 3 cycle first year , every 4-6 cycle ( need ) bone marrow aspirate check status disease . After Cycle 6 , number blood draw bone marrow collection may change . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Dasatinib FDA approve commercially available treatment patient certain type CML . Decitabine FDA approve treatment patient myelodysplastic syndrome . The combination drug treat CML investigational . Up 84 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients age 18 year age old CMLAP , CMLBP Philadelphia chromosomepositive acute myeloid leukemia define follow : CMLAP define presence 1529 % blast peripheral blood ( PB ) bone marrow ( BM ) , &gt; /= 20 % basophil PB BM , &gt; /= 30 % blast plus promyelocytes ( blast &lt; 30 % ) PB BM , &lt; 100 x10 ( 9 ) /L platelet unrelated therapy , clonal cytogenetics evolution ( i.e. , presence cytogenetic abnormality Philadelphia chromosome ) ; CMLBP define presence &gt; /= 30 % blast bone marrow and/or peripheral blood presence extramedullary disease . 2 . Patients eligible whether receive prior TKI therapy . For phase I portion study , patient receive prior therapy dasatinib able tolerate dose equivalent start dose dasatinib dose level patient enter . Patients previously receive dasatinib never dose propose eligible provide tolerated maximum dose prescribe grade 34 toxicity respond optimal management . 3 . ECOG performance status 03 . 4 . Men woman childbearing potential practice 2 method contraception ; 1 method must highly effective second method must either highly effective less effective . Men woman childbearing potential define : male surgically sterilize female amenorrheic least 12 consecutive month surgically sterilize . Patients must use birth control study 3 month last dose study drug sexually active . 5 . Women childbearing potential must pregnancy test screening . 6 . Signed informed consent . 7 . Patients must prior therapy CML 2 week prior start study therapy recover toxic effect therapy . Exceptions hydroxyurea TKIs ( include limit imatinib , nilotinib , bosutinib ) discontinue &gt; /= 24 hr prior start therapy . Patients receive dasatinib prior enrollment discontinue agent prior start study therapy . 8 . Adequate organ function : Serum creatinine &lt; /= 2.0 mg/dl creatinine clearance &gt; /=60 mL/min ; Total bilirubin &lt; /= 1.5 x ULN ( unless consider due Gilbert 's syndrome hemolysis ) ; Alanine aminotransferase ( ALT ) &lt; /= 3 x ULN unless consider due leukemic involvement . 1 . NYHA cardiac class 34 heart disease . 2 . Cardiac disease include : Uncontrolled angina within 3 month . Diagnosed suspected congenital long QT syndrome ; Any history clinically significant ventricular arrhythmia ( eg , ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; Prolonged QTc interval preentry electrocardiogram ( &gt; 470 msec ) Fridericia 's correction ; Uncontrolled hypertension ( define protocol sustain systolic BP &gt; /=150 diastolic &gt; /=100 ) ; Patients currently take drug generally accept risk cause Torsades de Pointes . 3 . Serious uncontrolled medical disorder uncontrolled active systemic infection current unstable decompensated respiratory cardiac condition make undesirable unsafe patient participate study . 4 . Patients know , clinically significant pericardial pleural effusion . 5 . History significant bleeding disorder unrelated cancer , include diagnose congenital bleeding disorder ( e.g. , von Willebrand 's disease ) , diagnose acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . 6 . Subject receive potent inhibitor CYP3A4 ; medication , washout period &gt; /= 7 day require prior start dasatinib unless discontinuation substitution inhibitor best interest patient determine investigator . These include follow medication : itraconazole , ketoconazole , miconazole , voriconazole ; amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir ; ciprofloxacin , clarithromycin , diclofenac , doxycycline , enoxacin , isoniazid , ketamine , nefazodone , nicardipine , propofol , quinidine , telithromycin . In instance use agent felt require best management patient , inclusion patient discuss PI rationale document . 7 . Females pregnant currently breastfeed . 8 . Patients eligible ( include available donor ) willing receive allogeneic stem cell transplant within 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Accelerated phase</keyword>
	<keyword>Blastic phase</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>